tbuckley/cabot-search huggingface dataset:
Abstract 2208: Interferon Consensus Sequence-Binding Protein (ICSBP) regulates the transforming growth factor-beta type I receptor expression in osteosarcoma cells
Authors: Jee Young Sung, Hyeryeong Kim, Kyung-Sil Yoon, Yong-Nyun Kim, Byung-Kiu Park
Journal: Cancer Research (2015)

Abstract Transforming growth factor-beta (TGF-β), known as a tumor suppressor, may exert tumor promoting activity in the advanced stage of cancer. Previously, we reported that interferon consensus sequence-binding protein (ICSBP), also known as interferon regulatory factor-8, up-regulates TGF-β type I receptor (TGF-βR I), and augments growth in HL-60 leukemic cells. In the current study, we demonstrate that ICSBP expression up-regulates TGF-βR I and increase in cell growth in U2OS human osteosarcoma cells. To further investigate the mechanism of TGF-βR I up-regulation by ICSBP, we tested the possibility that ICSBP regulates promoter activity of TGF-βR I gene. We analyzed the promoter region of the human TGF-βR I gene in U2OS cells to find putative transcription elements regulated by ICSBP. Luciferase reporter gene assays indicated that ICSBP expression could enhance TGF-βR I gene expression, and by promoter deletion analysis we identified a functional ICSBP-dependent region located at nucleotides -220 to +5 in the TGF-βR I promoter. We also performed EMSA (Electro Mobility Shift Assay) using probe and found that there are putative ICSBP binding sites between -222 to -204 regions. In conclusion, ICSBP increased TGF-βR I expression by binding to TGF-βR I promoter (-220/218) regions in U2OS cells. Note: This abstract was not presented at the meeting. Citation Format: Jee Young Sung, Hyeryeong Kim, Kyung-Sil Yoon, Yong-Nyun Kim, Byung-Kiu Park. Interferon Consensus Sequence-Binding Protein (ICSBP) regulates the transforming growth factor-beta type I receptor expression in osteosarcoma cells. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2208. doi:10.1158/1538-7445.AM2015-2208
Low doses of PM2.5 induces inflammation and oxidative stress with lung functional changes in mice
Authors: Walter Zin, Douglas Riva, Clarissa Magalhães, Paola Selmi, Daniel Marinho Laks, Tatiana Lanças, Thais Mauad, Olaf Malm, Paulo Saldiva, Debora Faffe
Journal: European Respiratory Journal (2008)
Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region
Authors: Maria E Grillet, Juan V Hernández-Villena, Martin S Llewellyn, Alberto E Paniz-Mondolfi, Adriana Tami, Maria F Vincenti-Gonzalez, Marilianna Marquez, Adriana C Mogollon-Mendoza, Carlos E Hernandez-Pereira, Juan D Plaza-Morr, Gabriella Blohm, Mario J Grijalva, Jaime A Costales, Heather M Ferguson, Philipp Schwabl, Luis E Hernandez-Castro, Poppy H L Lamberton, Daniel G Streicker, Daniel T Haydon, Michael A Miles, Alvaro Acosta-Serrano, Harry Acquattela, Maria G Basañez, Gustavo Benaim, Luis A Colmenares, Jan E Conn, Raul Espinoza, Hector Freilij, Mary C Graterol-Gil, Peter J Hotez, Hirotomo Kato, John A Lednicky, Clara E Martinez, Santiago Mas-Coma, J Glen Morris, Juan C Navarro, Jose L Ramirez, Marlenes Rodriguez, Julio A Urbina, Leopoldo Villegas, Maikell J Segovia, Hernan J Carrasco, James L Crainey, Sergio L B Luz, Juan D Moreno, Oscar O Noya Gonzalez, Juan D Ramírez, Belkisyolé Alarcón-de Noya
Journal: The Lancet Infectious Diseases (2019)
Case 57-1964
Authors: Irving P. Ackerman, Austin L. Vickery
Journal: New England Journal of Medicine (1964)

Presentation of CaseA twenty-nine-year-old man entered the hospital because of pain in the chest.He had been well until two months previously, when he experienced sharp pain in the anterior portion of the chest, with radiation to the posterior cervical region; the pain was aggravated by deep inspiration, sudden movement of the neck and leaning forward. During the week before admission he was anorectic, with fever, chilliness and a nonproductive cough; antibiotic medication was without benefit. On the day before entry dyspnea developed.There was no history of arthralgia, night sweats, weight loss, exposure to communicable disease, rheumatic fever, . . .
RNA-Seq Analysis of Clonal Hematopoiesis (CHIP) Blood Leukocytes Shows Dysregulation of Neutrophil / Innate Immunity-Related Genes
Authors: Elina K Cook, Richard N Armstrong, Eshita Sharma, Brooke Snetsinger, Jacqueline Boultwood, Rena Buckstein, Andrea Pellagatti, Michael J. Rauh
Journal: Blood (2018)
Hepatic gene expression of heat shock proteins (HSP) and PPAR alpha in experimental model of cirrhosis and hepatocellular carcinoma in nonoalcoholic fatty liver disease (NAFLD)
Authors: Vicencia M. Lima, Claudia P. Oliveira, Denise F Barbeiro, Jose Tadeu Stefano, Isabel Veloso, Hermes V. Barbeiro, Soriano Caldwell, Venancio A. Alves, Francisco G. Soriano, Heraldo P. Souza, Flair J. Carrilho
Journal: Hepatology (2008)
Haploinsufficiency of CALR Confers Hematopoietic Stem Cells (HSCs) with a Clonal Advantage over Wild-Type Cells, and, in Setting of Myeloproliferative Neoplasms, Compensates for the Functions of HSCs Impaired By the Calr Mutation
Authors: Kotaro Shide, Takuro Kameda, Ayako Kamiunten, Masaaki Sekine, Yoshinori Ozono, Takako Yokomizo, Keiichi Akizuki, Yuki Tahira, Yoko Kubuki, Tomonori Hidaka, Goro Sashida, Kazuya Shimoda
Journal: Blood (2018)
Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States, 2010–2012
Authors: Kamil E. Barbour, Charles G. Helmick, Kristina A. Theis, Louise B. Murphy, Jennifer M. Hootman, Teresa J. Brady, Yiling J. Cheng
Journal: MMWR Morbidity and Mortality Weekly Report (2013)
P092/O15 Synovial derived Th17-lymphocytes from patients with juvenile idiopathic arthritis induce cartilage degradation by synovial fibroblasts mediated by MMP9 in an experimental animal model
Authors: T Giani, F Margheri, M Del Rosso, L Maggi, F Annunziato, R Cimaz
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Career situation of first and presenting author</h3> Student for a master or a PhD. <h3>Introduction</h3> The synovial fluid of Juvenile idiopathic Arthritis (JIA) is rich of Th17 and of Th-17-derived CD4+ CD161+ cells, also called non-classic-Th1. How such subpopulations drive the JIA joint damage is still a subject of great interest especially in light of the possible use of biological drugs able to selectively inhibit the activity of specific cytokines. <h3>Objectives</h3> To clarify the role of Th17 and non-classical Th1 lymphocytes in the pathogenesis of joint cartilage destruction by synovial fibroblasts (SFbs). <h3>Methods</h3> The role of different subsets of CD4+T cells was observed in the activation of SFbs in terms of cartilage degradation by normal and JIA SFbs and induction of proteases both <i>in vitro</i> and <i>in vivo</i>, using a SCID Mouse model through the 'inverse wrap' implantation technique. <h3>Results</h3> JIA SFbs produce large amounts of MMP9 and efficiently degrade fragments of human cartilage wrapped in a collagen matrix containing the fibroblasts themselves and grafted under-skin on SCID mice (the 'inverse wrap model'). Similar effects were observed with SFbs of healthy subjects incubated with conditioned media of Th17 and of non-classic Th1. We shown that Th17 induce MMP9 in SFbs, while non-classic Th1 act mainly by inducing urokinase-plasminogen-activator over-activity. <h3>Conclusions</h3> IL-17 triggers the pathogenic chain leading to joint damage in patients with JIA. <h3>References</h3> Maggi L, <i>et al</i>. T cell subpopulations in juvenile idiopathis arthritis and their modifications after biotherapies. <i>Autoimmun Rev</i> 2016;15:1141–44. Nistala K, <i>et al</i>. Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment. <i>Proc Natl Acad Sci U S A</i> 2010;107:14751–6. Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. <i>N Engl J Med.</i> 2009 August 27;361:888–98. Maggi L, <i>et al</i>. Judex M, <i>et al</i>. 'Inverse wrap': an improved implantation technique for virus transduced synovial fibroblasts in the SCID mouse model forrheumatoid arthritis. <i>Mod Rheumatol</i> 2001;11:145–50. Del Rosso M, <i>et al</i>. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. <i>Clin Exp Metastasis</i> 2002;19:193–207. Beringer A, Noack M, Miossec P. L-17 in Chronic Inflammation: From Discovery to Targeting. <i>Trends Mol Med</i> 2016 March;22:230–241. Miossec P. Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice. <i>RMD Open</i> 2017 February 15;3. <h3>Disclosure of Interest</h3> None declared.
THU0621 Persistent pruritic skin lesions with dyskeratotic cells in upper layer of epidermis are specific and associated with high levels of serum il-18 in adult-onset still’s disease
Authors: H. Nishikawa, Y. Taniguchi, N. Maeda-Aoyama, K. Nakajima, S. Inotani, Y. Shimamura, K. Inoue, K. Arii, S. Sano, Y. Terada
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Adult-onset Still's disease <b>(</b>AOSD) is an acute and systemic inflammatory disorder that is characterised by high spiking fever, evanescent rash, arthralgia/arthritis and hyperferritinemia. However, recent reports showed that not only typical evanescent salmon-coloured rash but also atypical skin lesions, persistent pruritic papules and plaques, could be associated with AOSD. <h3>Objectives</h3> To assess the clinical significance of dyskeratotic cells (DCs) in skin lesions of AOSD. <h3>Methods</h3> We assessed histology of skin lesions including persistent pruritic skin lesions in Japanese patients with AOSD (n=15). Moreover, we compared histology of AOSD with dermatomyositis (DM) (n=6), drug eruptions (DE) (n=7), and graft versus host disease (GVHD) (n=6). <h3>Results</h3> AOSD with persistent pruritic skin lesions (n=10) histologically showed DCs only in upper layer of epidermis and horny layer without inflammatory cells infiltrations, indicating dyskeratosis. AOSD with evanescent rash (n=5) histologically showed no DCs. DCs were positive by ssDNA staining, suggesting apoptotic cells. Serum IL-18 showed significantly higher in AOSD patients with dyskeratosis (n=10) than without dyskeratosis (n=5). In contrast to AOSD with DCs, the histology of DM, DE and GVHD demonstrated that DCs existed in all layers of epidermis with inflammatory cells infiltrations. <h3>Conclusions</h3> Persistent pruritic skin lesions in AOSD are specific by prominent epidermal apoptosis involving the upper layers of epidermis. Moreover, hyper IL-18 might be related with dyskeratosis. <h3>Disclosure of Interest</h3> None declared
The 18-year-old clinical trial inclusion limit is a major barrier in the access to immunotherapies and targeted therapies for adolescents and young adults (AYAs) with cancer
Authors: T. de Rojas, A. Neven, M. Garcia-Abos, L. Moreno, N. Gaspar, J. Peron
Journal: Annals of Oncology (2019)

Background: The 18-years-old age limit for inclusion in clinical trials constitutes a major hurdle for adolescents and young adults (AYAs) with cancer that the main stakeholders are advocating to overthrow. The purpose of this study was 1) to analyze the access for adolescents with cancer to targeted therapies and immunotherapies and to innovation (measured in number of mechanisms of action –MoA-), when compared to young adults; and 2) to describe the time lapse between the first adult trial for a specific drug and the first trial recruiting adolescents for that same drug. Methods: ClinicalTrials.gov was searched to identify all the clinical trials including patients with malignancies relevant for AYAs (Hodgkin lymphoma, anaplastic large cell lymphoma, extracranial germ cell tumors, medulloblastoma, rhabdomyosarcoma, synovial sarcoma, Ewing sarcoma, osteosarcoma, melanoma, thyroid cancer), starting between Jan/2007-Jul/2018. Only trials investigating immunotherapies and/or targeted therapies were included. The trials, drugs, and MoA were categorized as "available for adolescents" (including patients 12-18 years old) and "available for young adults" (18-25 years). Results: Out of 2765 identified trials, 1369 were included: 1352 (99%) available for young adults vs 233 (17%) available for adolescents. A total of 384 novel drugs (target therapies or immunotherapies) were investigated, all 384 available for young adults vs 108 (28%) for adolescents. All 184 investigated MoA were accessible for young adults vs 61 (33%) for adolescents. Out of the 108 drugs investigated in adolescents for the included malignancies, 59 were investigated first in adults, with a median delay of 35 months (IQR 23-60). No time trend in this delay was observed over the years of the study. Conclusions: There is a major gap in the access to novel drugs and innovation between adolescents and young adults, with the 18-years-old limit posing a large barrier. There is also a prominent delay in the opening of trials for adolescents, with no improvement observed over the last decade. Greater efforts are needed to improve clinical research for AYAs with cancer. Legal entity responsible for the study: EORTC. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Drug Repositioning Inferred from E2F1-Coregulator Interactions Studies for the Prevention and Treatment of Metastatic Cancers
Authors: Deborah Goody, Shailendra K. Gupta, David Engelmann, Alf Spitschak, Stephan Marquardt, Stefan Mikkat, Claudia Meier, Charlotte Hauser, Jan-Paul Gundlach, Jan-Hendrik Egberts, Hubert Martin, Toni Schumacher, Anna Trauzold, Olaf Wolkenhauer, Stella Logotheti, Brigitte M. Pützer
Journal: Theranostics (2019)

Metastasis management remains a long-standing challenge.High abundance of E2F1 triggers tumor progression by developing protein-protein interactions (PPI) with coregulators that enhance its potential to activate a network of prometastatic transcriptional targets.Methods: To identify E2F1-coregulators, we integrated high-throughput Co-immunoprecipitation (IP)/mass spectometry, GST-pull-down assays, and structure modeling.Potential inhibitors of PPI discovered were found by bioinformatics-based pharmacophore modeling, and transcriptome profiling was conducted to screen for coregulated downstream targets.Expression and target gene regulation was validated using qRT-PCR, immunoblotting, chromatin IP, and luciferase assays.Finally, the impact of the E2F1-coregulator complex and its inhibiting drug on metastasis was investigated in vitro in different cancer entities and two mouse metastasis models. Results:We unveiled that E2F1 forms coactivator complexes with metastasis-associated protein 1 (MTA1) which, in turn, is directly upregulated by E2F1.The E2F1:MTA1 complex potentiates hyaluronan synthase 2 (HAS2) expression, increases hyaluronan production and promotes cell motility.Disruption of this prometastatic E2F1:MTA1 interaction reduces hyaluronan synthesis and infiltration of tumor-associated macrophages in the tumor microenvironment, thereby suppressing metastasis.We further demonstrate that E2F1:MTA1 assembly is abrogated by small-molecule, FDA-approved drugs.Treatment of E2F1/MTA1-positive, highly aggressive, circulating melanoma cells and orthotopic pancreatic tumors with argatroban prevents metastasis and cancer relapses in vivo through perturbation of the E2F1:MTA1/HAS2 axis.Conclusion: Our results propose argatroban as an innovative, E2F-coregulator-based, antimetastatic drug.Cancer patients with the infaust E2F1/MTA1/HAS2 signature will likely benefit from drug repositioning.
SP0197 Improving Your Graphs and Tables for Publication and Presentation
Authors: M. Boers
Journal: Annals of the Rheumatic Diseases (2014)

<h3></h3> This is a repeat of the workshop given on Friday 13.06.2014 at 13.30. This workshop is an introduction to the principles of good graph and table design as pioneered by Cleveland [1] and Tufte [2] and updated by Few [3] so that the participant can better answer the following questions: <h3>Which of the messages in my research results requires a graph or table?</h3> Recognizing how graphs improve on simple statistics and convey much more information. Knowing when a table is better, or keeping the data in the body text. <h3>How can I best convey the message?</h3> Striving for clear vision by choice of graph, scaling, discrimination of data series, minimizing non-data ink, avoiding chart junk.Striving for clear understanding through a balance between data and explanation. Using order, subheadings, formatting and rules to guide your reader through your table data. <h3>Is my graph/table truthful?</h3> Creating a direct proportion between graph and data quantities, avoiding forms prone to misinterpretation, labels to prevent ambiguity; keeping data in context, avoiding more dimensions in the graph than in the data. <h3>References</h3> Cleveland WS. The elements of graphing data: Hobart Press, Summit, NJ, U.S.A.; 1994. Tufte E. The visual display of quantitative information. 2nd ed: Graphics Press, Cheshire, CT, U.S.A.; 2001. Few S. Show me the numbers. Designing tables and graphs to enlighten. Analytics Press, Oakland, CA, U.S.A.; 2004. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.6162
Reply
Authors: Jiaye Liu, Tao Li, Li Zhang, Aiqiang Xu
Journal: Hepatology (2019)

Potential conflict of interest: Nothing to report. We read the comments by Jeng et al. with great interest and would like to clarify a few issues raised on our systematic review.1 We did not include the study of Wang CC AJG 2016 and Tseng CH J Formos Med Assoc 2018 for unavailable relapse data in the setting of different hepatitis B surface antigen (HBsAg) levels at the end of treatment (EOT). We also excluded the study of Hsu YC CGH 2016 because only minimum entecavir treatment time was emphasized without consideration of consolidation therapy after achieving hepatitis B e antigen (HBeAg) seroconversion or undetectable HBV DNA when patients discontinued entecavir. Chen et al.2 reported that the virological relapse rates were 24.8%, 77.2%, and 77.9% at 36 months off‐therapy for patients whose HBeAg were negative, and HBsAg at EOT were <150, 150‐500, and >500 IU/mL, respectively, which were in accord with our conclusions and should be a strong support for conclusions in our review.1 Furthermore, Jeng WJ 2013 was included for the analysis of off‐therapy clinical relapse, and Jeng WJ 2018 was included for the analysis of HBsAg loss in our review. We were well aware of the differences in HBV DNA low detection limit and definition of off‐therapy virological relapse. However, we were be able to use a standardized definition for the limited data reported in the included studies. A standard nomenclature is required to better estimate the rate of off‐therapy relapse. Besides age, HBeAg status, baseline DNA, HBsAg at EOT, and consolidation therapy time, the type of nucleos(t)ide analogues (NAs) could be another important factor associating with off‐therapy outcomes. However, it is quite difficult to propose specific HBsAg cutoff at EOT for different NAs because of limited studies. Basing on current evidences, we proposed that HBsAg level <100 IU/mL at EOT could be an important addition for cessation criteria of current guidelines. However, more well‐designed studies were needed to explore the optimal HBsAg cutoff at EOT for patients with different clinical status and receiving different NAs. Although only <20% patients could reach HBsAg level <100 IU/mL at EOT after 3 years of entecavir treatment as Jeng WJ, et al. mentioned, this treatment goal was more feasible compared with HBsAg loss. However, further studies on the risk and benefit of NA cessation in the setting of HBsAg level <100 IU/mL at EOT are still required in the future. It is well known that there is high frequency for HBV genotype C in Northeastern China; by contrast, HBV genotype is dominated by B type in Southern China and Taiwan.
Concurrent Pancreatic Metastasis From Lung Adenocarcinoma and Primary Cholangiocarcinoma on FDG PET/CT Imaging
Authors: Wei Wang, Ying Kan, Xu Yang, Jie Liu, Jigang Yang
Journal: Clinical Nuclear Medicine (2019)

A 67-year-old man with a history of left upper lobe resection of poorly differentiated adenocarcinoma 1 year ago underwent FDG PET/CT for restaging. The images demonstrated a round cystic lesion with peripheral FDG uptake and centrally photopenic region. Additional focus of increased activity was detected in the left lobe of the liver. The patient underwent the Whipple and partial hepatectomy. The surgical pathology demonstrated concurrently the metastasis to the pancreas from the lung adenocarcinoma and a primary moderately differentiated cholangiocarcinoma.
Duration of Treatment of Multiple Myeloma Regimens in Patients with Relapsed or Refractory Multiple Myeloma: Findings in US Clinical Practice Settings
Authors: Ravi Potluri, Hemanth Kanakamedala, Clara Chen, Christopher A. Yasenchak, Sandip Ranjan, Eros Papademetriou, Hitesh Bhandari, Jasdeep Mann, Catherine Davis
Journal: Blood (2017)
Abstract 11623: Determination of the Diagnostic Accuracy of a Mobile Smartphone ECG Device Compared to a Standard 12-Lead ECG for Evaluation of ST-Segment Elevation Myocardial Infarction (STEMI). Primary Results of the ST LEUIS International Multicenter Study
Authors: Joseph B Muhlestein, Charles F Bethea, Harry W Severance, Alejandro Barbagelata, Robert J Mentz, David Albert, Gregory W Barsness, Viet T Le, T J Bunch, Frank Yanowitz, Benjamin Chisum, Heidi T May, Brianna S Ronnow, Jay Widmer, Jeffrey L Anderson
Journal: Circulation (2018)

Background: Patients with STEMI who receive rapid diagnosis and reperfusion therapy have improved clinical outcomes. The rate-limiting step in STEMI diagnosis is often the availability of a 12-lead...
Ectopic Pregnancy—United States, 1988-1989
Authors: H K Atrash, J M Hughes, C J Hogue
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Aspiration and injection of joints (1).
Authors: P Williams, M Gumpel
Journal: BMJ (1980)

ASPIRATION AND INJECTION OF JOINTS (1)Therapeutic injection of joints and periarticular structures is simple: the ability to perform this procedure as primary care may save the patient needless waiting for hospital appointments.Examination of synovial fluid for diagnostic purposes in patients with unexplained or acute synovitis may be vital: familiarity with the technique will increase the likelihood of obtaining such fluid. S(1) Diagnostic aspiration in cases of suspected septic arthritis, crystalinduced synovitis, and haemarthrosis.' ~~~~~(2) Therapeutic aspiration for tense effusions, septic effusions, and haemarthrosis.(3) Therapeutic injections of corticosteroids for persistent localised synovitis or soft-tissue lesions.